Suppr超能文献

分支型支架象鼻吻合术冷冻主动脉弓修复:来自医师发起的研究性器械豁免研究的早期结果。

Branched stented anastomosis frozen elephant trunk repair: Early results from a physician-sponsored investigational device exemption study.

机构信息

Aortic Center, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio; Department of Thoracic and Cardiovascular Surgery, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio.

Aortic Center, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio; Department of Thoracic and Cardiovascular Surgery, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio.

出版信息

J Thorac Cardiovasc Surg. 2024 Sep;168(3):746-756. doi: 10.1016/j.jtcvs.2023.09.069. Epub 2023 Oct 5.

Abstract

BACKGROUND

Multisegment thoracic aortic disease typically requires total aortic arch replacement, affects a heterogenous population, and carries a high risk even at centers of excellence. Risk has been associated with the duration of operation and complexity of repair. A novel branched stented anastomosis frozen elephant trunk repair (B-SAFER) technique has been developed at our center and is currently being studied as a physician-sponsored investigation device exemption (PS-IDE).

OBJECTIVE

This study aimed to assess the early safety of using this investigational technique to treat the proximal aorta in subjects with aortic disease involving multiple segments.

METHODS

This prospective, single center, nonrandomized study enrolled patients undergoing B-SAFER for acute aortic syndrome (n = 73), aortic aneurysm with chronic aortic dissection (n = 68), degenerative aortic aneurysm (n = 33), or congenital aortic arch disease (n = 4). Devices are delivered antegrade under hypothermic circulatory arrest, and the arch reconstruction is performed as a single anastomosis single stent (SASS; n = 70), single anastomosis multiple stent (SAMA; n = 68), multiple anastomosis single stent (MASS; n = 21), or multiple anastomosis multiple stent (MAMS; n = 16) reconstruction. The primary safety endpoints were operative mortality, disabling stroke, and paraparesis/paralysis.

RESULTS

Between May 27, 2021, and December 31, 2022, 178 patients underwent B-SAFER in the configurations and for the indications as described above. The median patient age was 65 years (range, 21 to 85 years), and 52 (29%) were female. The median cardiopulmonary bypass time was 188 minutes (interquartile range [IQR], 155 to 226 minutes), and 97% of the patients underwent repair with antegrade brain perfusion for a median of 46 minutes (IQR, 38 to 61 minutes). Operative mortality occurred in 10 patients (5.6%, including 6 [8.2%] with acute dissection, 2 [2.9%] with chronic dissection, 2 [6.1%] with degenerative aneurysm, and 0 with a congenital disorder), disabling stroke in 5 patients (2.9%), and paraparesis in 1 patient. Other serious complications included respiratory failure (n = 20; 11.4%) and acute kidney injury (n = 18; 10%). Thirty-two patients (18%) had undergone second-stage repairs (28 endovascular and 4 open), with 1 operative mortality after that procedure due to distal rupture. Estimated survival was 95% at 30 days, 88% at 90 days, 84% at 6 months, and 79% at 1 year. One-year survival differed by indication (72% for acute dissection, 91% for chronic dissection, 71% for degenerative aneurysm, and 100% for congenital disorders).

CONCLUSIONS

The B-SAFER technique for total arch replacement in a complex cohort of patients with various indications for surgery is a safe and reproducible operation, as demonstrated by the early results from a very inclusive PS-IDE study. Further follow-up and analysis will help refine the technique. Novel devices to perform this procedure should be developed.

摘要

背景

多节段胸主动脉疾病通常需要进行全主动脉弓置换,涉及异质人群,即使在卓越中心也存在高风险。风险与手术持续时间和修复复杂性相关。我们中心开发了一种新型分支支架吻合冷冻象鼻修复(B-SAFER)技术,目前正在作为医师发起的研究设备豁免(PS-IDE)进行研究。

目的

本研究旨在评估使用该研究技术治疗多节段主动脉疾病患者近端主动脉的早期安全性。

方法

这是一项前瞻性、单中心、非随机研究,纳入了因急性主动脉综合征(n=73)、慢性主动脉夹层合并主动脉瘤(n=68)、退行性主动脉瘤(n=33)或先天性主动脉弓疾病(n=4)而行 B-SAFER 治疗的患者。器械在低温循环停止下经逆行输送,弓部重建采用单一吻合单一支架(SASS;n=70)、单一吻合多支架(SAMA;n=68)、多吻合单一支架(MASS;n=21)或多吻合多支架(MAMS;n=16)重建。主要安全性终点是手术死亡率、致残性中风和截瘫/瘫痪。

结果

2021 年 5 月 27 日至 2022 年 12 月 31 日期间,178 名患者接受了上述配置和适应证的 B-SAFER。患者中位年龄为 65 岁(范围为 21 至 85 岁),52 名(29%)为女性。中位体外循环时间为 188 分钟(四分位距 [IQR],155 至 226 分钟),97%的患者接受了顺行脑灌注修复,中位时间为 46 分钟(IQR,38 至 61 分钟)。10 名患者(5.6%,包括 6 名[8.2%]急性夹层、2 名[2.9%]慢性夹层、2 名[6.1%]退行性动脉瘤和 0 名先天性疾病)发生手术死亡率,5 名(2.9%)发生致残性中风,1 名发生截瘫。其他严重并发症包括呼吸衰竭(n=20;11.4%)和急性肾损伤(n=18;10%)。32 名(18%)患者进行了二期修复(28 例血管内和 4 例开放),此后 1 例因远端破裂而死亡。术后 30 天估计生存率为 95%,90 天为 88%,6 个月为 84%,1 年为 79%。1 年生存率因适应证而异(急性夹层为 72%,慢性夹层为 91%,退行性动脉瘤为 71%,先天性疾病为 100%)。

结论

B-SAFER 技术用于治疗各种手术适应证的复杂患者的全主动脉弓置换是一种安全且可重复的手术,这从非常包容的 PS-IDE 研究的早期结果中得到了证明。进一步的随访和分析将有助于完善该技术。应开发用于进行此程序的新型设备。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验